Keywords: Takeda, Revestive, Short bowel syndrome, SBS, European approval, NPS Pharma

Takeda's Revestive gets EU clearance for short bowel syndrome

Article | 05 September 2012

Japan’s largest drugmaker Takeda Pharmaceutical (TSE: 4502) and partner NPS Pharmaceuticals (Nasdaq: NPSP) said yesterday that the European Commission ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Takeda Pharmaceuticals

NPS Pharmaceuticals

Go to company listing

Related Drugs

Revestive

Go to drug listing